Enhanced Genomics Raises $19M Series A To Expand Drug Discovery Pipeline

Enhanced Genomics, a Cambridge, UK-based drug discovery startup spun out from the Babraham Institute, has closed additional funding to increase its Series A round to $19 million. The firm is advancing its 3D multiomics platform, GenLink, that identifies genetically validated drug targets across diseases including autoimmune conditions. Recent partnerships include collaboration with the Alborada Drug Discovery Institute focusing on Alzheimer’s disease targets. The new capital will fuel pipeline expansion and strategic alliances with pharma and biotech partners.